Recent research has demonstrated that NSC-sEVs treated with Catalpol exhibit increased expression of miR-138-5p, which targets Tau and inhibits its accumulation, thereby impeding the progression of AD (56). This evidence concerns the gene MAPT and Alzheimer disease.